Cargando…
Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara
INTRODUCTION: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoa...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060281/ https://www.ncbi.nlm.nih.gov/pubmed/23557279 http://dx.doi.org/10.1186/ar4207 |
_version_ | 1782321350985121792 |
---|---|
author | Petri, Marcelo H Satoh, Minoru Martin-Marquez, Beatriz T Vargas-Ramírez, Raul Jara, Luis J Saavedra, Miguel A Cruz-Gonzalez, Claudia Andrade-Ortega, Lilia Vera-Lastra, Olga Salazar-Páramo, Mario Prieto-Parra, Rosa E Gonzalez-Lopez, Laura Gamez-Nava, Jorge I Ramírez-Sánchez, Hermes U Chan, Jason YF Ross, Steven J Chan, Edward KL Vázquez-Del Mercado, Mónica |
author_facet | Petri, Marcelo H Satoh, Minoru Martin-Marquez, Beatriz T Vargas-Ramírez, Raul Jara, Luis J Saavedra, Miguel A Cruz-Gonzalez, Claudia Andrade-Ortega, Lilia Vera-Lastra, Olga Salazar-Páramo, Mario Prieto-Parra, Rosa E Gonzalez-Lopez, Laura Gamez-Nava, Jorge I Ramírez-Sánchez, Hermes U Chan, Jason YF Ross, Steven J Chan, Edward KL Vázquez-Del Mercado, Mónica |
author_sort | Petri, Marcelo H |
collection | PubMed |
description | INTRODUCTION: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoantibodies and the clinical manifestations of PM/DM were evaluated comparing two cohorts in Mexico. METHODS: Ninety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied. Autoantibodies were characterized by immunoprecipitation using (35)S-methionine labeled K562 cell extract. Clinical information was obtained from medical records. RESULTS: DM represented 69% of PM/DM and anti-Mi-2 was the most common autoantibody (35%), followed by anti-p155/140 (11%); however, anti-Jo-1 was only 4%. The autoantibody profile in adult-onset DM in Mexico City versus Guadalajara showed striking differences: anti-Mi-2 was 59% versus 12% (P = 0.0012) whereas anti-p155/140 was 9% versus 35% (P = 0.02), respectively. A strong association of anti-Mi-2 with DM was confirmed and when clinical features of anti-Mi-2 (+) DM (n = 30) versus anti-Mi-2 (-) DM (n = 36) were compared, the shawl sign (86% versus 64%, P < 0.05) was more common in the anti-Mi-2 (+) group (P = 0.0001). Levels of creatine phosphokinase (CPK) were higher in those who were anti-Mi-2 (+) but they responded well to therapy. CONCLUSIONS: Anti-Mi-2 has a high prevalence in Mexican DM and is associated with the shawl sign and high CPK. The prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City versus Guadalajara, which have a similar UV index. This suggests roles of factors other than UV in anti-Mi-2 antibody production. |
format | Online Article Text |
id | pubmed-4060281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40602812014-06-17 Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara Petri, Marcelo H Satoh, Minoru Martin-Marquez, Beatriz T Vargas-Ramírez, Raul Jara, Luis J Saavedra, Miguel A Cruz-Gonzalez, Claudia Andrade-Ortega, Lilia Vera-Lastra, Olga Salazar-Páramo, Mario Prieto-Parra, Rosa E Gonzalez-Lopez, Laura Gamez-Nava, Jorge I Ramírez-Sánchez, Hermes U Chan, Jason YF Ross, Steven J Chan, Edward KL Vázquez-Del Mercado, Mónica Arthritis Res Ther Research Article INTRODUCTION: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoantibodies and the clinical manifestations of PM/DM were evaluated comparing two cohorts in Mexico. METHODS: Ninety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied. Autoantibodies were characterized by immunoprecipitation using (35)S-methionine labeled K562 cell extract. Clinical information was obtained from medical records. RESULTS: DM represented 69% of PM/DM and anti-Mi-2 was the most common autoantibody (35%), followed by anti-p155/140 (11%); however, anti-Jo-1 was only 4%. The autoantibody profile in adult-onset DM in Mexico City versus Guadalajara showed striking differences: anti-Mi-2 was 59% versus 12% (P = 0.0012) whereas anti-p155/140 was 9% versus 35% (P = 0.02), respectively. A strong association of anti-Mi-2 with DM was confirmed and when clinical features of anti-Mi-2 (+) DM (n = 30) versus anti-Mi-2 (-) DM (n = 36) were compared, the shawl sign (86% versus 64%, P < 0.05) was more common in the anti-Mi-2 (+) group (P = 0.0001). Levels of creatine phosphokinase (CPK) were higher in those who were anti-Mi-2 (+) but they responded well to therapy. CONCLUSIONS: Anti-Mi-2 has a high prevalence in Mexican DM and is associated with the shawl sign and high CPK. The prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City versus Guadalajara, which have a similar UV index. This suggests roles of factors other than UV in anti-Mi-2 antibody production. BioMed Central 2013 2013-04-04 /pmc/articles/PMC4060281/ /pubmed/23557279 http://dx.doi.org/10.1186/ar4207 Text en Copyright © 2013 Petri et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Petri, Marcelo H Satoh, Minoru Martin-Marquez, Beatriz T Vargas-Ramírez, Raul Jara, Luis J Saavedra, Miguel A Cruz-Gonzalez, Claudia Andrade-Ortega, Lilia Vera-Lastra, Olga Salazar-Páramo, Mario Prieto-Parra, Rosa E Gonzalez-Lopez, Laura Gamez-Nava, Jorge I Ramírez-Sánchez, Hermes U Chan, Jason YF Ross, Steven J Chan, Edward KL Vázquez-Del Mercado, Mónica Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara |
title | Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara |
title_full | Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara |
title_fullStr | Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara |
title_full_unstemmed | Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara |
title_short | Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara |
title_sort | implications in the difference of anti-mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from mexico city and guadalajara |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060281/ https://www.ncbi.nlm.nih.gov/pubmed/23557279 http://dx.doi.org/10.1186/ar4207 |
work_keys_str_mv | AT petrimarceloh implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT satohminoru implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT martinmarquezbeatrizt implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT vargasramirezraul implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT jaraluisj implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT saavedramiguela implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT cruzgonzalezclaudia implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT andradeortegalilia implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT veralastraolga implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT salazarparamomario implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT prietoparrarosae implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT gonzalezlopezlaura implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT gameznavajorgei implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT ramirezsanchezhermesu implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT chanjasonyf implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT rossstevenj implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT chanedwardkl implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara AT vazquezdelmercadomonica implicationsinthedifferenceofantimi2andp155140autoantibodyprevalenceintwodermatomyositiscohortsfrommexicocityandguadalajara |